IP Library Granted Patent US 10,195,223
Granted Patent B2
US 10,195,223 · App. 16/002,888 · Granted Feb 5, 2019

Dosage forms for oral administration of zoledronic acid or related compounds for treating disease

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/675A61K9/0053A61K9/20A61K9/2004A61K9/48A61K31/4164A61K31/4172C07D233/60C07F9/6506A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,223
App. No.
16/002,888
Granted
Feb 5, 2019
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions.

Claims (22)

1. A method of delivering zoledronic acid to the blood comprising orally administering a dosage form to a human being in need of treatment with zoledronic acid, wherein the dosage form comprises zoledronic acid, wherein the human being fasts for at least 2 hours before the dosage form is administered and the human being fasts for at least 1 hour after the dosage form is administered, and wherein the method results in a bioavailability of the zoledronic acid that is about 1.8% to about 2.3% in the human being.

2. The method of claim 1 , wherein the dosage form is administered to treat arthritis pain.

3. The method of claim 1 , wherein the dosage form is administered to treat low back pain.

4. The method of claim 1 , wherein the zoledronic acid is in a salt form.

5. The method of claim 4 , wherein the zoledronic acid is administered to treat an inflammatory pain.

6. The method of claim 5 , wherein the zoledronic acid is in a disodium salt form.

7. The method of claim 1 , wherein the dosage form is administered about weekly.

8. The method of claim 7 , wherein the dosage form contains about 30 mg to about 100 mg of the zoledronic acid.

9. The method of claim 8 , wherein the dosage form is administered to treat arthritis pain.

10. The method of claim 8 , wherein the dosage form is administered to treat low back pain.

11. The method of claim 1 , wherein the dosage form is administered about 2 or 3 times in a month.

12. The method of claim 11 , wherein the dosage form contains about 50 mg to about 150 mg of the zoledronic acid.

13. The method of claim 12 , wherein the dosage form is administered to treat arthritis pain.

14. The method of claim 12 , wherein the dosage form is administered to treat low back pain.

15. The method of claim 1 , wherein the dosage form is administered about once a month.

16. The method of claim 15 , wherein the dosage form contains about 100 mg to about 300 mg of the zoledronic acid.

17. The method of claim 16 , wherein the dosage form is administered to treat arthritis pain.

18. The method of claim 16 , wherein the dosage form is administered to treat low back pain.

19. The method of claim 1 , wherein the dosage form is administered daily.

20. The method of claim 19 , wherein the dosage form contains about 0.5 mg to about 10 mg of the zoledronic acid.

21. The method of claim 20 , wherein the dosage form is administered to treat arthritis pain.

22. The method of claim 20 , wherein the dosage form is administered to treat low back pain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2018
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 046320/0873 →
Continuity (15)
Continuation 15702616 · Sep 12, 2017
Continuation In Part 15604394 · May 24, 2017
Continuation In Part 15348808 · Nov 10, 2016
Continuation In Part 15211827 · Jul 15, 2016
Continuation 14968514 · Dec 14, 2015
Continuation 14540333 · Nov 13, 2014
Continuation 14481097 · Sep 9, 2014
Continuation 14288720 · May 28, 2014
Continuation 14288241 · May 27, 2014
Continuation In Part PCTUS2015032739 · May 27, 2015
Continuation PCTUS2014050427 · Aug 8, 2014
Continuation 14279241 · May 15, 2014
Continuation In Part 15587108 · May 4, 2017
Provisional Application 62378140 · Aug 22, 2016
Related Publication 20180280416A1 · Oct 4, 2018